Solifenacin: Scientific evidence in the treatment of overactive bladder;Solifenacina: Evidencia científica en el tratamiento de la vejiga hiperactiva

Archivos Espanoles de Urologia

Volumn 63, Issue 3, 2010, Pages 197-213

  Santos, Javier Cambronero ^a   Telo, Eduardo R Zungri ^b  

^a HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^b HOSPITAL POVISA   (Spain)

Author keywords

Antimuscarinics; Efficacy; Overactive bladder; Solifenacin; Tolerability; Urgency

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDIN 3' YL 1 PHENYL 1,2,3,4 TETRAHYDROISOQUINOLINE 2 CARBOXYLATE MONOSUCCINATE; QUINUCLIDIN-3'-YL-1-PHENYL-1,2,3,4-TETRAHYDROISOQUINOLINE-2-CARBOXYLATE MONOSUCCINATE; QUINUCLIDINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ARTICLE; CLINICAL TRIAL (TOPIC); HUMAN; OVERACTIVE BLADDER; QUALITY OF LIFE; RETROSPECTIVE STUDY;

CLINICAL TRIALS AS TOPIC; HUMANS; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; QUINUCLIDINES; RETROSPECTIVE STUDIES; TETRAHYDROISOQUINOLINES; URINARY BLADDER, OVERACTIVE;

EID: 77957700261     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21:167-178 (Pubitemid 34195211)
2. Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2009; 28(4): 293.
3. Chapple CR, Rosenberg MT, Brenes FJ. Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome. BJU Int 2009; 104(7): 960-967
4. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-1315
5. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-766
6. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams, P.; Herzog, A.R.; Corey, R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-336 (Pubitemid 44175300)
7. Robinson, D.; Cardozo, L. Solifenacin: pharmacology and clinical efficacy. Expert Rev Clin Pharmacol 2009; 2(3): 239-253.
8. Wagner TH, Hu TW, Bentkover J, Le Blanc, K.; Stewart, W.; Corey, R, et al. Health-related consequences of overactive bladder. Am J Manag Care 2002; 8(19 suppl.):S598-S607.
9. Hu TW, Wagner TH. Health-related consequences of overactive bladder: an economic perspective. BJU Int 2005; 96(1): 43-45
10. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergics drugs versus placebo for overactive bladder syndrom in adults. Cochrane Database Syst. Rev. 4 2006, CD003781.
11. Ohtake A, Ukai M, Hatanaka T, Kobayashi, S, Ikeda, K, Sato, S, et al. In vitro and in vivo tissu selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004; 492: 243-250
12. Chapple, C.R. Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder. Expert Opin Pharmacother 2006; 7(17): 2421-2434
13. Vesicare Summary of Product Characteristics
14. Vardy M.D, Mitcheson, H.D, Samuels, T.A, Wengeke, J.D, Forero-Schwanhaeuser, S, Marshall, T.S et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. Int J Clin Pract 2009; 63(12): 1702-1714.
15. Haab F, Cardozo L, Chapple C, Ridder, A.M. Long-term open label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005;47:376-384
16. Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson, P.; Warnack, W.; Drogendijk, T et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48(3):464-470
17. Cardozo L, Hessdoerfer, E, Milani, R, Araño, P, Dewilde, L, Slack, M, et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008; 102(9): 1120-1127
18. Appell RA. Recent clinical studies of new pharmacologic agents and their efficacy in the treatment of incontinence. Rev Urol 2001; 3 (Suppl 1): S15-8.
19. Zinner N, Gittleman M, Harris R, Susset J, Kanelos A, Auerbach S. R et al. Trospiun chloride improves overactive bladder symptoms: a multicenter Phase III trial. J Urol 2004; 171(6 Pr 1): 2311-2315
20. Abrams P, Cardozo L, Chapple CR, Serdarevic, D, Hargreaves, K, Khullar, V. Comparison of the efficacy, safety and tolerability of propiverine and oxybutinin for the treatment of overactive bladder syndrome. Int J Urol 2006; 13(6): 692-698
21. Nitti VW, Dmochowski R, Appel RA, Wang, J.T, Bavendam, T, Guan, Z.H. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU Int 2006; 97(6): 1262-1266
22. Payne CK. Solifenacin in overactive bladder syndrome. Drugs 2006; 66(2): 175-190
23. Chapple CR, Rechberger T, Al-Shukri S, Meffan, P, Everaert, K, Huang, M, et al. Randomized, double-blind placebo controlled and tolterodine controlled trial of the once daily antimuscarinic agent solifenacin in patients with symptomatic overactive badder. BJU Int 2004; 93(3):303-310
24. Cardozo L, Lisec M, Millard R, van Vierssen Trip, O, Kuzmin, I, Drogendijk T.E, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172:1919-1924
25. Chu F, Smith N, Uchida T. Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Current Ther Res 2009; 70 (6): 405-420
26. Dmochowski R, Staskin, D.R . The Q-T interval and antimuscarinic drugs. Curr Urol Rep 2005;6(6):405-409
27. Krauwinkel WJ, Smulders RA, Mulder H, Swart PJ, Taekema-Roelvink ME. Effect of age on the phamacokinetics of solifenacin in men and women. Int J Clin Pharmacol Ther 2005; 43(5): 227-238
28. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tole rability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006; 4(1): 14-24.
29. Michel, M C, Wetterauer U, Vogel M, de la Rosette J J M H. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use. Drug Safety 2008;31(6):505-514
30. Wesnes KA, Edgar C, Tretter R, Bolodeoku J. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf 2009; 8(6): 615-626
31. Swart PJ, Krauwinkel WJ, Smulders RA, Smith NN. Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers. Basic Clin Pharmacol Toxicol 2006; 99: 33-36
32. Taekema-Roelvink ME, Swart PJ, Kuipers ME, Krauwinkel WJ, Visser N, Smulders RA. Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double blind, placebo controlled study. Clin Ther 2005; 27: 1403-1410
33. Smulders RA, Kuipers MA, Krauwinkel WJJ. Multiple doses of the antimuscarinic agent solifenacin do not affect the phamacodynamics or pharmacokinetics of warfarin of the steady-state pharmacokinetics of digoxin in healthy subjects. Br J Clin Pharmacol 2006; 62: 210-217
34. Smulders RA, Smith NN, Krauwinkel WJ, Hoon TJ. Phamacokinetics, safety and tolerability of solifenacin in patient with renal insufficiency. J. Pharmacol Sci 2007; 103: 67-74.
35. Kuipers M, Smulders R, Krauwinkel W, Hoon T. Open label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment. J Phamacol Sci 2006; 102: 405-412
36. Chapple CR, Araño P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo and tolterodine controlled Phase II dose finding study. BJU Int 2004; 93(1): 71-77
37. Chapple CR, Araño P, Bosch JLHR, De Ridder D, Kramer G, Ridder AM. YM905 appears effective and well tolerated in patients with symptomatic idiophatic detrusor overactivity in an european placebo and tolterodine controlled Phase II dose finding study. Neurourol Urodyn 2002; 21 (4): 381-382
38. Gittleman MC. The efficacy and safety of solifenacin in adults with overactive bladder; a multicentre, placebo controlled study. Int J Gynaecol Obstet 2003; 83 (Suppl 3): 94.
39. Gittelman, M.; Chu, F.M.; Klimberg, I.; Fincher, R.; Smith, N.; Tempel, D et al. Two randomized, double-blind, placebo-controlled, parallel-group, fixed- dose, multicenter studies assess the efficacy and safety of daily oral administration of 10 mg YM905 versus placebo in male and female subjects with overactive bladder. J Urol 2003 169(4 Suppl): 349
40. Cardozo L, Chapple C, Steers W, Govier F. Solifenacin improves all symptoms of overactive bladder syndrome. Neurourol Urodyn 2005; 24(5-6): Abstr. 300
41. Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 2006; 60(8): 959-966
42. Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne KS et al. Test-retest realiability of four questionnaires for patients with overactive bladder: The overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn 2005; 24: 215-225
43. Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 2009; 73(1): 14-18.
44. Toglia MR, Serels SR, Laramee C, Karma MM, Nandy IM, Andoh M, et al. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Posgraduate Med 2009; 121(5): 151-158
45. Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial. Clin Ther 2006; 28(11):1935-1946.
46. Sand PK, Steers WD, Dmochowski R, Andoh M, Forero-Schwanhaeuser S. Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin. Int Urogynecol J Pelvic Floor Dysfunct. 2009; 20(6):667-675
47. Zinner N, Noe L, Rasouliyan L, Marshall T, Seifeldin R. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER. Curr Med Res Opin 2008; 24(6): 1583-1591
48. Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami, P et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study: Clin Ther 2008; 30(10):1766-1781
49. Michel MC, de la Rosette JJMCH. Role of muscarinic receptor antagonist in urgency and nocturia. BJU Int 2005; 96(Suppl. 1): 37-42.
50. Debruyne FM, Heesakkers JP. Clinical and socioeconomic relevance of overactive bladder. Urology 2004; 63 (3 Suppl. 1): 42-44
51. Epstein LB, Goldberg RP. The overactive bladder and quality of life. Int J Fertil Women Med 2005; 50(1): 30-36
52. Mullins CD, Subak LL. New perspectives on overactive bladder: quality of life impact, medication persistency, and treatment costs. Am J Manag Care 2005; 1(4 Suppl.): S101-2.
53. Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality of life consideration. Drugs 2004; 64(15): 1643-1656
54. Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005; 95:81-85
55. van Leeuwen JHS, Castro R, Busse M, Bemelmans BLH. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 2006. 50: 440-453